Filing Details

Accession Number:
0001209191-14-073880
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-12-09 16:25:34
Reporting Period:
2014-12-04
Filing Date:
2014-12-09
Accepted Time:
2014-12-09 16:25:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1131324 Genomic Health Inc GHDX Services-Medical Laboratories (8071) 770552594
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1337798 Bradley G Cole 301 Penobscot Drive
Redwood City CA 94063
Coo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-12-04 1,307 $0.00 21,645 No 5 G Direct
Common Stock Acquisiton 2014-12-08 4,336 $9.39 25,981 No 4 M Direct
Common Stock Disposition 2014-12-08 4,336 $32.52 21,645 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 5 G Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2014-12-08 4,336 $0.00 0 $9.39
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
33,664 2015-12-01 No 4 M Direct
Footnotes
  1. These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 22, 2013.
  2. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
  3. Represents weighted average sale price. Actual sale prices ranged from $32.07 to $32.85.
  4. Includes an aggregate of 12,655 shares of common stock issuable pursuant to previously reported restricted stock unit awards that have not vested.
  5. The option became exercisable as to 25% of the shares on December 1, 2006, and becomes exercisable as to 1/48th of the shares each full month thereafter.